Overview
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
Status:
Completed
Completed
Trial end date:
2013-10-01
2013-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Incyte Corporation
Criteria
Inclusion Criteria:- Subjects with active RA aged 18 to 75 years of age and meet tender and swollen joint
assessment expectations defined in the study protocol.
- c-Reactive protein (CRP) or erythrocyte sedimentation rate (ESR) laboratory values
meet minimal study protocol expectations.
Exclusion Criteria:
- Females who are pregnant or breastfeeding.
- Men and women who cannot comply with requirements to avoid fathering a child or
becoming pregnant, respectively.
- Subjects treated with a biologic agent within 12 weeks prior to first dose of study
drug. (12 months in the case of rituximab.)
- Subjects with a history or currently suspected inflammatory disease other than RA.
- Subjects with a history of hematological disorders.